Unity Biotechnology Performance
| UBXDelisted Stock | USD 0.16 0.01 6.67% |
The entity has a beta of -0.14, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Unity Biotechnology are expected to decrease at a much lower rate. During the bear market, Unity Biotechnology is likely to outperform the market. Unity Biotechnology right now has a risk of 0.0%. Please validate Unity Biotechnology jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Unity Biotechnology will be following its existing price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Unity Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Unity Biotechnology is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 20.7 M | |
| Total Cashflows From Investing Activities | 8.6 M |
Unity |
Unity Biotechnology Relative Risk vs. Return Landscape
If you would invest 16.00 in Unity Biotechnology on October 30, 2025 and sell it today you would earn a total of 0.00 from holding Unity Biotechnology or generate 0.0% return on investment over 90 days. Unity Biotechnology is generating negative expected returns assuming volatility of 0.0% on return distribution over 90 days investment horizon. In other words, 0% of stocks are less volatile than Unity, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Unity Biotechnology Target Price Odds to finish over Current Price
The tendency of Unity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.16 | 90 days | 0.16 | close to 99 |
Based on a normal probability distribution, the odds of Unity Biotechnology to move above the current price in 90 days from now is close to 99 (This Unity Biotechnology probability density function shows the probability of Unity Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon Unity Biotechnology has a beta of -0.14. This usually implies as returns on the benchmark increase, returns on holding Unity Biotechnology are expected to decrease at a much lower rate. During a bear market, however, Unity Biotechnology is likely to outperform the market. Additionally Unity Biotechnology has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Unity Biotechnology Price Density |
| Price |
Predictive Modules for Unity Biotechnology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Unity Biotechnology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Unity Biotechnology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Unity Biotechnology is not an exception. The market had few large corrections towards the Unity Biotechnology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Unity Biotechnology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Unity Biotechnology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -2.17 | |
β | Beta against Dow Jones | -0.14 | |
σ | Overall volatility | 0.21 | |
Ir | Information ratio | -0.24 |
Unity Biotechnology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Unity Biotechnology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Unity Biotechnology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Unity Biotechnology is not yet fully synchronised with the market data | |
| Unity Biotechnology has some characteristics of a very speculative penny stock | |
| Unity Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (25.99 M) with loss before taxes, overhead, and interest of (12.06 M). | |
| Unity Biotechnology has about 64.51 M in cash with (20.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Pasithea Therapeutics Upgraded at Wall Street Zen |
Unity Biotechnology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Unity Stock often depends not only on the future outlook of the current and potential Unity Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Unity Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 16.8 M | |
| Cash And Short Term Investments | 23.2 M |
Unity Biotechnology Fundamentals Growth
Unity Stock prices reflect investors' perceptions of the future prospects and financial health of Unity Biotechnology, and Unity Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Unity Stock performance.
| Return On Equity | -2.31 | |||
| Return On Asset | -0.39 | |||
| Current Valuation | 3.53 M | |||
| Shares Outstanding | 17.21 M | |||
| Price To Book | 2.59 X | |||
| Price To Sales | 6.54 X | |||
| EBITDA | (25.12 M) | |||
| Cash And Equivalents | 64.51 M | |||
| Cash Per Share | 9.26 X | |||
| Total Debt | 23.54 M | |||
| Debt To Equity | 1.30 % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (20.86 M) | |||
| Earnings Per Share | (1.63) X | |||
| Total Asset | 37.66 M | |||
| Retained Earnings | (510.34 M) | |||
About Unity Biotechnology Performance
Evaluating Unity Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Unity Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Unity Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Unity Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people.Things to note about Unity Biotechnology performance evaluation
Checking the ongoing alerts about Unity Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Unity Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Unity Biotechnology is not yet fully synchronised with the market data | |
| Unity Biotechnology has some characteristics of a very speculative penny stock | |
| Unity Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (25.99 M) with loss before taxes, overhead, and interest of (12.06 M). | |
| Unity Biotechnology has about 64.51 M in cash with (20.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Pasithea Therapeutics Upgraded at Wall Street Zen |
- Analyzing Unity Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Unity Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Unity Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Unity Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Unity Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Unity Biotechnology's stock. These opinions can provide insight into Unity Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Unity Stock
If you are still planning to invest in Unity Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Unity Biotechnology's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |